Search research articles
Contact Us
Filters
Showing results (291-300 of 319) with videos related to
Page
of 32
Sort By:
The British Journal of Dermatology
|
July 15, 2017
Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients
Y Teramoto, U Keim, A Gesierich, et al.
Der Pathologe
|
June 14, 2012
[BRAF mutation detection in metastatic melanoma]
M Dietel, A Enk, A Lehmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2008
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)
K Spieth, R Kaufmann, R Dummer, et al.
Nature Aging
|
February 21, 2022
Evidence for accelerated aging in mammary epithelia of women carrying germline <i>BRCA1</i> or <i>BRCA2</i> mutations
Sundus F Shalabi, Masaru Miyano, Rosalyn W Sayaman, et al.
Frontiers in Cell and Developmental Biology
|
May 3, 2018
Microenvironment-Induced Non-sporadic Expression of the AXL and cKIT Receptors Are Related to Epithelial Plasticity and Drug Resistance
Tiina A Jokela, Agnete S T Engelsen, Agata Rybicka, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 25, 2021
Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition
J J Grob, A Guminski, J Malvehy, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 23, 2021
Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas
J J Grob, C Gaudy-Marqueste, A Guminski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2016
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial
T K Eigentler, R Gutzmer, A Hauschild, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2016
Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study
G A McArthur, M Maio, A Arance, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 12, 2011
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial
F Egberts, R Gutzmer, S Ugurel, et al.
Page
of 32
Search research articles
Search
Showing results (291-300 of 319) with videos related to
Sort By:
Page
of 32
The British Journal of Dermatology
|
July 15, 2017
Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients
Y Teramoto, U Keim, A Gesierich, et al.
Der Pathologe
|
June 14, 2012
[BRAF mutation detection in metastatic melanoma]
M Dietel, A Enk, A Lehmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2008
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)
K Spieth, R Kaufmann, R Dummer, et al.
Nature Aging
|
February 21, 2022
Evidence for accelerated aging in mammary epithelia of women carrying germline <i>BRCA1</i> or <i>BRCA2</i> mutations
Sundus F Shalabi, Masaru Miyano, Rosalyn W Sayaman, et al.
Frontiers in Cell and Developmental Biology
|
May 3, 2018
Microenvironment-Induced Non-sporadic Expression of the AXL and cKIT Receptors Are Related to Epithelial Plasticity and Drug Resistance
Tiina A Jokela, Agnete S T Engelsen, Agata Rybicka, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 25, 2021
Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition
J J Grob, A Guminski, J Malvehy, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 23, 2021
Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas
J J Grob, C Gaudy-Marqueste, A Guminski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2016
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial
T K Eigentler, R Gutzmer, A Hauschild, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2016
Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study
G A McArthur, M Maio, A Arance, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 12, 2011
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial
F Egberts, R Gutzmer, S Ugurel, et al.
Page
of 32